<DOC>
	<DOCNO>NCT00317356</DOCNO>
	<brief_summary>The purpose study examine safety efficacy OPC-6535 ( tetomilast ) determine optimal dose once-daily oral administration 0 , 12.5 , 25 , 50 mg 8 week combination fix oral dose 5-aminosalicylic acid ( 5-ASA ) patient active ulcerative colitis .</brief_summary>
	<brief_title>A Dose-Finding Study OPC-6535 Patients With Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Patients active ulcerative colitis Patients receive oral 5ASA formulation fix regimen fix dose Either inpatient outpatient Patients history intestinal resection ( appendiceal resection ) Patients complication malignant tumor Female patient pregnant , lactate , possibly pregnant , wish become pregnant study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>OPC-6535</keyword>
	<keyword>ulcerative colitis</keyword>
</DOC>